Europe Bleeding Disorders Treatment Market

Europe Bleeding Disorders Treatment Market Size & Growth (2022 to 2027):

As per the research report, the size of the Europe Bleeding Disorders Treatment Market is valued at USD 3.11 billion in 2022 and is estimated to be growing at a CAGR of 7.75%, to reach USD 4.52 billion by 2027 during the forecast period 2022 to 2027.

The coagulation disorder treatment market in Europe is experiencing an increase due to the growth in the number of patients with bleeding disorders, increased research and development activities and investments by key players, awareness-raising increased bleeding disorders and favorable government initiatives.

The most common is hemophilia A with a prevalence between 1: 5,000 and 1: 10,000 in men. Hemophilia B is less common, with a majority between 1: 35,000 and 1: 50,000 men, although acquired hemophilia is rare to find among the population in the United Kingdom. According to the annual survey report of the World Federation of Hemophilia, an estimated 17,500 million people have hemophilia.

European countries have a large customer base with favorable compensation policies; this also drives the market during the analysis period. In addition, the expiration of patents on existing brands will also allow generic drug manufacturers to enter the lucrative Europe bleeding disorder treatment market.

Additionally, the increasing prevalence of liver disorders, anemia, and drugs affecting blood clotting factors like aspirin will increase the demand for treatment for bleeding disorders. The growing number of establishments are working with extensive diagnostic and treatment centers helping market growth. The advancement in technology for diagnosis and treatment are also creating lucrative growth opportunities in the Europe bleeding disorder treatment market.

However, the lack of access to adequate treatment due to the high cost of drugs and the shortage of qualified healthcare professionals is hampering the growth of the Europe bleeding disorders treatment market.

This research report on the Europe Bleeding Disorders Treatment Market has been segmented and sub-segmented into the following categories:

By Drug Class: 

• Fibrin Sealant
• Desmopressin
• Antibrinolytics
• Recombinant Coagulation Factor Concentrates
• Plasma Derived Coagulation Factor Concentrates

By Type:

• vWD
• Hemophilia A
• Hemophilia B

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the U.K. Bleeding Disorders Treatment Market represents the largest share in the Europe bleeding disorder treatment market and will continue to develop its dominant position during the period due to the high rate of adoption of prophylactic treatments to avoid complications, a growing number of affected patients, increased spending with the presence of well-developed health care infrastructure. In addition, the growth of the bleeding disorder care industry is driven by favorable reimbursement plans coupled with insurance.

In the U.K., the prevalence of anemia was found to be 25% in a national multi-center study by Barroso et al. In another bicentric English study; it was found that 47% of women had anemia, especially during pregnancy, according to Nair et al. This increasing prevalence of bleeding disorders with the availability of treatments modalities will provide growth opportunities for the bleeding disorder treatment market.

The German Bleeding Disorders Treatment Market is anticipated to have the second-largest market share. Various factors such as increased research expenditure, technological advancement, and high for innovative and effective therapies drive the market growth in this region.

According to the Statista website, approximately 149,800 people were diagnosed with hemophilia A, and about 10,820 people were diagnosed with other platelet disorders. Most individuals in Germany suffer from some bleeding disorder during their lifetime. By WHO estimates, anemia was present in about 30.99% of females and 9.45% of males; we can also note that the hemoglobin levels were lower than among Germans compared to other European nations.

The France Bleeding Disorders Treatment Market is estimated to grow with a steady CAGR soon due to the access to optimal healthcare facilities, supportive government initiatives, advanced technologies, and better healthcare needs.

KEY MARKET PLAYERS

Key players operating in the Europe Bleeding Disorders Treatment Market profiled in this report are CSL Behring, Pfizer Inc., Novo Nordisk, Bayer AG, Biogen Inc., Shire Plc., Medline Plus, Janssen Europe Services, LLC, and Grifos SA.,